Robin Ortiz1, Mark J Niciu1, Nada Lukkahati2, Leorey N Saligan3, Allison C Nugent1, David A Luckenbaugh1, Rodrigo Machado-Vieira1, Carlos A Zarate4. 1. National Institutes of Health/National Institute of Mental Health, Experimental Therapeutics & Pathophysiology Branch, Building 10/Clinical Research Center (CRC), 10 Center Dr., Room 7-5342, Bethesda, MD 20892, USA. 2. National Institute of Nursing Research, National Institutes of Health, Bethesda, MD, USA; School of Nursing, University of Nevada at Las Vegas, Las Vegas, NV, USA. 3. National Institute of Nursing Research, National Institutes of Health, Bethesda, MD, USA. 4. National Institutes of Health/National Institute of Mental Health, Experimental Therapeutics & Pathophysiology Branch, Building 10/Clinical Research Center (CRC), 10 Center Dr., Room 7-5342, Bethesda, MD 20892, USA. Electronic address: zaratec@mail.nih.gov.
Abstract
BACKGROUND: Shank3, a post-synaptic density protein involved in N-methyl-d-aspartate (NMDA) receptor tethering and dendritic spine rearrangement, is implicated in the pathophysiology of bipolar disorder. We hypothesized that elevated baseline plasma Shank3 levels might predict antidepressant response to the NMDA receptor antagonist ketamine. METHODS:Twenty-nine subjects with bipolar depression received a double-blind, randomized, subanesthetic dose (.5 mg/kg) ketamine infusion. Of the patients for whom Shank3 levels were collected, 15 completed baseline 3-Tesla MRI and 17 completed post-ketamine [(18)F]-FDG PET. RESULTS: Higher baseline Shank3 levels predicted antidepressant response at Days 1 (r=-.39, p=.047), 2 (r=-.45, p=.02), and 3 (r=-.42, p=.03) and were associated with larger average (r=.58, p=.02) and right amygdala volume (r=.65, p=.009). Greater baseline Shank3 also predicted increased glucose metabolism in the hippocampus (r=.51, p=.04) and amygdala (r=.58, p=.02). LIMITATIONS: Limitations include the small sample size, inability to assess the source of peripheral Shank3, and the lack of a placebo group for baseline Shank3 levels and comparative structural/functional neuroimaging. CONCLUSIONS: Shank3 is a potential biomarker of antidepressant response to ketamine that correlates with baseline amygdala volume and increased glucose metabolism in the amygdala and hippocampus. Published by Elsevier B.V.
RCT Entities:
BACKGROUND:Shank3, a post-synaptic density protein involved in N-methyl-d-aspartate (NMDA) receptor tethering and dendritic spine rearrangement, is implicated in the pathophysiology of bipolar disorder. We hypothesized that elevated baseline plasma Shank3 levels might predict antidepressant response to the NMDA receptor antagonist ketamine. METHODS: Twenty-nine subjects with bipolar depression received a double-blind, randomized, subanesthetic dose (.5 mg/kg) ketamine infusion. Of the patients for whom Shank3 levels were collected, 15 completed baseline 3-Tesla MRI and 17 completed post-ketamine [(18)F]-FDG PET. RESULTS: Higher baseline Shank3 levels predicted antidepressant response at Days 1 (r=-.39, p=.047), 2 (r=-.45, p=.02), and 3 (r=-.42, p=.03) and were associated with larger average (r=.58, p=.02) and right amygdala volume (r=.65, p=.009). Greater baseline Shank3 also predicted increased glucose metabolism in the hippocampus (r=.51, p=.04) and amygdala (r=.58, p=.02). LIMITATIONS: Limitations include the small sample size, inability to assess the source of peripheral Shank3, and the lack of a placebo group for baseline Shank3 levels and comparative structural/functional neuroimaging. CONCLUSIONS:Shank3 is a potential biomarker of antidepressant response to ketamine that correlates with baseline amygdala volume and increased glucose metabolism in the amygdala and hippocampus. Published by Elsevier B.V.
Authors: Mehreen Kouser; Haley E Speed; Colleen M Dewey; Jeremy M Reimers; Allie J Widman; Natasha Gupta; Shunan Liu; Thomas C Jaramillo; Muhammad Bangash; Bo Xiao; Paul F Worley; Craig M Powell Journal: J Neurosci Date: 2013-11-20 Impact factor: 6.167
Authors: Allison C Nugent; David A Luckenbaugh; Suzanne E Wood; Wendy Bogers; Carlos A Zarate; Wayne C Drevets Journal: Hum Brain Mapp Date: 2012-07-19 Impact factor: 5.038
Authors: J Shen; K F Petersen; K L Behar; P Brown; T W Nixon; G F Mason; O A Petroff; G I Shulman; R G Shulman; D L Rothman Journal: Proc Natl Acad Sci U S A Date: 1999-07-06 Impact factor: 11.205
Authors: Carlos A Zarate; Nancy E Brutsche; Lobna Ibrahim; Jose Franco-Chaves; Nancy Diazgranados; Anibal Cravchik; Jessica Selter; Craig A Marquardt; Victoria Liberty; David A Luckenbaugh Journal: Biol Psychiatry Date: 2012-01-31 Impact factor: 13.382
Authors: Allison C Nugent; Nancy Diazgranados; Paul J Carlson; Lobna Ibrahim; David A Luckenbaugh; Nancy Brutsche; Peter Herscovitch; Wayne C Drevets; Carlos A Zarate Journal: Bipolar Disord Date: 2013-09-18 Impact factor: 6.744
Authors: Nicolas D Iadarola; Mark J Niciu; Erica M Richards; Jennifer L Vande Voort; Elizabeth D Ballard; Nancy B Lundin; Allison C Nugent; Rodrigo Machado-Vieira; Carlos A Zarate Journal: Ther Adv Chronic Dis Date: 2015-05 Impact factor: 5.091
Authors: Gustavo C Medeiros; Todd D Gould; William L Prueitt; Julie Nanavati; Michael F Grunebaum; Nuri B Farber; Balwinder Singh; Sudhakar Selvaraj; Rodrigo Machado-Vieira; Eric D Achtyes; Sagar V Parikh; Mark A Frye; Carlos A Zarate; Fernando S Goes Journal: Mol Psychiatry Date: 2022-06-27 Impact factor: 15.992
Authors: Megha M Vasavada; Amber M Leaver; Randall T Espinoza; Shantanu H Joshi; Stephanie N Njau; Roger P Woods; Katherine L Narr Journal: J Affect Disord Date: 2015-11-18 Impact factor: 4.839
Authors: D D Kiraly; S R Horn; N T Van Dam; S Costi; J Schwartz; S Kim-Schulze; M Patel; G E Hodes; S J Russo; M Merad; D V Iosifescu; D S Charney; J W Murrough Journal: Transl Psychiatry Date: 2017-03-21 Impact factor: 6.222